Bradley Conor P, Orchard Vanessa, McKinley Gemma, Heggie Robert, Wu Olivia, Good Richard, Watkins Stuart, Lindsay Mitchell, Eteiba Hany, McGowan James, McGeoch Ross, Corcoran David, Kellman Peter, McConnachie Alex, Berry Colin
School of Cardiovascular and Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK; Department of Cardiology, NHS Golden Jubilee Hospital, Clydebank, Scotland, UK.
Department of Cardiology, NHS Golden Jubilee Hospital, Clydebank, Scotland, UK.
Am Heart J. 2023 Nov;265:213-224. doi: 10.1016/j.ahj.2023.08.067. Epub 2023 Aug 30.
Coronary microvascular dysfunction may cause myocardial ischemia with no obstructive coronary artery disease (INOCA). If functional testing is not performed INOCA may pass undetected. Stress perfusion cardiovascular MRI (CMR) quantifies myocardial blood flow (MBF) but the clinical utility of stress CMR in the management of patients with suspected angina with no obstructive coronary arteries (ANOCA) is uncertain.
First, to undertake a diagnostic study using stress CMR in patients with ANOCA following invasive coronary angiography and, second, in a nested, double-blind, randomized, controlled trial to assess the effect of disclosure on the final diagnosis and health status in the longer term.
All-comers referred for clinically indicated coronary angiography for the investigation of suspected coronary artery disease will be screened in 3 regional centers in the United Kingdom. Following invasive coronary angiography, patients with ANOCA who provide informed consent will undergo noninvasive endotyping using stress CMR within 3 months of the angiogram.
Stress perfusion CMR imaging to assess the prevalence of coronary microvascular dysfunction and clinically significant incidental findings in patients with ANOCA. The primary outcome is the between-group difference in the reclassification rate of the initial diagnosis based on invasive angiography versus the final diagnosis after CMR imaging.
RANDOMIZED, CONTROLLED TRIAL: Participants will be randomized to inclusion (intervention group) or exclusion (control group) of myocardial blood flow to inform the final diagnosis. The primary outcome of the clinical trial is the mean within-subject change in the Seattle Angina Questionnaire summary score (SAQSS) at 6 months. Secondary outcome assessments include the EUROQOL EQ-5D-5L questionnaire, the Brief Illness Perception Questionnaire (Brief-IPQ), the Treatment Satisfaction Questionnaire (TSQM-9), the Patient Health Questionnaire-4 (PHQ-4), the Duke Activity Status Index (DASI), the International Physical Activity Questionnaire- Short Form (IPAQ-SF), the Montreal Cognitive Assessment (MOCA) and the 8-item Productivity Cost Questionnaire (iPCQ). Health and economic outcomes will be assessed using electronic healthcare records.
To clarify if routine stress perfusion CMR imaging reclassifies the final diagnosis in patients with ANOCA and whether this strategy improves symptoms, health-related quality of life and health economic outcomes.
GOV: NCT04805814.
冠状动脉微血管功能障碍可能导致无阻塞性冠状动脉疾病(INOCA)的心肌缺血。如果不进行功能测试,INOCA可能无法被检测到。负荷灌注心血管磁共振成像(CMR)可量化心肌血流量(MBF),但负荷CMR在疑似无阻塞性冠状动脉(ANOCA)心绞痛患者管理中的临床效用尚不确定。
第一,在侵入性冠状动脉造影后的ANOCA患者中使用负荷CMR进行诊断研究;第二,在一项嵌套的双盲、随机、对照试验中,评估信息披露对最终诊断和长期健康状况的影响。
在英国的3个地区中心,对因临床指征进行冠状动脉造影以调查疑似冠状动脉疾病的所有患者进行筛查。侵入性冠状动脉造影后,提供知情同意的ANOCA患者将在血管造影后3个月内使用负荷CMR进行无创分型。
负荷灌注CMR成像,以评估ANOCA患者冠状动脉微血管功能障碍的患病率和具有临床意义的偶然发现。主要结局是基于侵入性血管造影的初始诊断与CMR成像后的最终诊断的重新分类率的组间差异。
参与者将被随机分为纳入(干预组)或排除(对照组)心肌血流量以告知最终诊断。临床试验的主要结局是6个月时西雅图心绞痛问卷总结评分(SAQSS)的受试者内平均变化。次要结局评估包括欧洲生活质量EQ-5D-5L问卷、简短疾病认知问卷(Brief-IPQ)、治疗满意度问卷(TSQM-9)、患者健康问卷-4(PHQ-4)、杜克活动状态指数(DASI)、国际体力活动问卷简表(IPAQ-SF)、蒙特利尔认知评估(MOCA)和8项生产力成本问卷(iPCQ)。将使用电子医疗记录评估健康和经济结局。
明确常规负荷灌注CMR成像是否能对ANOCA患者的最终诊断进行重新分类,以及该策略是否能改善症状、健康相关生活质量和健康经济结局。
GOV:NCT04805814